Curasight A/S is a clinical development company. It engages in the business of exploiting a novel theragnostic platform with positron emissions tomography imaging and radionuclide therapy targeting the urokinase-type plasminogen activator receptor. The company was founded by Morten Persson, Andreas Kjær, Carsten Haagen Nielsen, and Jacob Madsen in 2013 and is headquartered in Copenhagen, Denmark.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company